Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of…
| Price | $11.07 |
|---|---|
| Market cap | $380.3M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 9.85-16.76 |
| Beta | 0.27 |
Explore BNTC's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.